Euthymics Bioscience Receives $24,000,000 Series A Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=81f1b07e-bf5a-441d-880b-e461bb098f5f&Preview=1 -
Date
7/22/2010 -
Company Name
Euthymics Bioscience -
Mailing Address
35 Braintree Hill Office Park Braintree, MA 02184 -
Company Description
Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment. -
Website
http://www.Euthymics.com -
Transaction Type
Venture Equity -
Transaction Amount
$24,000,000 -
Transaction Round
Series A -
Proceeds Purposes
The initial Series A proceeds were used to complete the acquisition of DOV Pharmaceutical, Inc. and allow for the continued development of DOV’s unique antidepressant, EB-1010 (formerly known as DOV 21,947), for patients who do not respond adequately to selective serotonin reuptake inhibitors, or SSRIs. -
M&A Terms
-
Venture Investor
Novartis Venture Fund -
Venture Investor
Venture Investors -
Venture Investor
Hambrecht & Quist Capital Management -
Venture Investor
GBS Venture Partners
